Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

Identifying lung cancer at its earliest stage before symptoms develop allows for earlier treatment and the potential for cure ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients.

The risk for lung cancer is especially high among those with rheumatoid arthritis who also have interstitial lung disease.